Telitacicept

Product Description

Telitacicept (Tai'ai®) is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept is being developed by Yantai Rongchang Pharmaceutical through its subsidiary RemeGen for the treatment of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34463932/)

Mechanisms of Action: BLyS Inhibitor,APRIL Inhibitor

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Subcutaneous

FDA Designation:
Fast Track - Erythema|Lupus Erythematosus|Lupus Erythematosus, Systemic
Fast Track - Sjogren's Syndrome
Orphan Drug - Myasthenia Gravis|Asthenia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: RemeGen
Company Location:
Company CEO:
Additional Commercial Interests: None